Vivo Capital, a global investment powerhouse with deep roots in healthcare, is thrilled to announce the successful closing of a $740 million funding round. Founded in 1996 and headquartered in Palo Alto, California, with key offices in Singapore and Beijing, Vivo Capital has a longstanding legacy of excellence and innovation in the financial sector. With approximately $5.3 billion in assets under management and an impressive portfolio that includes investments in over 430 public and private companies worldwide, the firm has been instrumental in advancing healthcare solutions across biotechnology, pharmaceuticals, medical devices, and healthcare services. The robust team, comprised of 75 seasoned professionals including physicians, scientists, entrepreneurs, and industry experts, has consistently driven Vivo Capital鈥檚 commitment to excellence in investment strategies, spanning private equity, growth, venture capital, and public equities.
This latest infusion of capital is strategically earmarked to fuel further expansion in high-potential areas of healthcare. Vivo Capital aims to harness this funding to escalate investments in breakthrough technologies and emerging trends that promise to redefine patient care and medical innovation globally. The additional funds will empower the firm to support transformative projects and foster beneficial partnerships that not only advance scientific research but also enhance healthcare delivery systems around the world. As Vivo Capital charts its path forward, it remains steadfast in its mission to combine financial acumen with industry expertise, thereby driving sustainable value creation for its investors and contributing to the evolution of global healthcare.
